Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 7:07 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 4,563 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo A tablet Clear all

Conditions: Smoking Cessation, Depression
Interventions: varenicline, placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 525 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 17
States / cities: Garden Grove, California • Sherman Oaks, California • Aurora, Colorado + 13 more

Conditions: Colorectal Cancer
Interventions: Vandetanib, FOLFIRI; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 4
States / cities: Ann Arbor, Michigan • New York, New York • Nashville, Tennessee + 1 more

Conditions: Primary Progressive Multiple Sclerosis, Primary Progressive MS, Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive MS (SPMS), Secondary Progressive Multiple Sclerosis (SPMS), Secondary Progressive MS, Non-Active SPMS, Non-Active Secondary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis With Inflammatory Disease Activity
Interventions: SUN-627, Placebo; Drug · Other
Lead sponsor: Sundance Biosciences, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 7
States / cities: Tampa, Florida • Atlanta, Georgia • Stony Brook, New York + 4 more

Conditions: Rheumatoid Arthritis
Interventions: Abatacept, Methotrexate, Abatacept placebo, Methotrexate placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 511 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 15
States / cities: Huntsville, Alabama • Hot Springs, Arkansas • Sarasota, Florida + 12 more

Conditions: Diabetes
Interventions: HTI-2088, Placebo; Drug
Lead sponsor: Hengrui Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: anamorelin HCl, placebo; Drug
Lead sponsor: Helsinn Therapeutics (U.S.), Inc; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 19
States / cities: Little Rock, Arkansas • Melbourne, Florida • Augusta, Georgia + 12 more

Conditions: Long QT Syndrome Type 3
Interventions: Eleclazine, Eleclazine placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 3
States / cities: Rochester, Minnesota • New York, New York • Rochester, New York

Conditions: Schizophrenia
Interventions: NaBen®, Placebo; Drug
Lead sponsor: SyneuRx International (Taiwan) Corp; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 20
States / cities: Dothan, Alabama • Bellflower, California • Long Beach, California + 17 more

Conditions: Major Depressive Disorder
Interventions: Placebo, Vilazodone; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 529 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 52
States / cities: Imperial, California • Los Angeles, California • Murrieta, California + 46 more

Conditions: Breast Cancer, Insomnia
Interventions: Suvorexant Tablets, Placebo Control; Drug · Other
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older · Female only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Prostatic Neoplasms
Interventions: Pembrolizumab, Enzalutamide, Placebo; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 28
States / cities: Mobile, Alabama • Fullerton, California • Los Angeles, California + 25 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: PH-797804, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 377 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 22
States / cities: Mobile, Alabama • Glendale, Arizona • San Diego, California + 17 more

Conditions: PTSD
Interventions: TNX-102 SL, Placebo; Drug
Lead sponsor: Tonix Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 23
States / cities: Tuscaloosa, Alabama • Phoenix, Arizona • Imperial, California + 20 more

Conditions: Atherosclerosis, Percutaneous Coronary Intervention, Acute Coronary Syndrome
Interventions: cangrelor P2Y12 (platelet) inhibitor, Clopidogrel - 300 or 600 mg (study arm), Clopidogrel 600 mg post cangrelor; Drug
Lead sponsor: The Medicines Company; Industry
Eligibility: 18 Years and older
Enrollment: 11,145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Anderson, South Carolina

Conditions: Dementia With Lewy Bodies
Interventions: RVT-101 35 mg, RVT-101 70 mg, Placebo; Drug
Lead sponsor: Axovant Sciences Ltd.; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 484 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 31
States / cities: Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 26 more

Conditions: Depressive Disorder, Major
Interventions: Desvenlafaxine Succinate Sustained-Release (DVS SR), Placebo, Duloxetine 60 mg/day; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 638 participants
Timeline: 2006 – 2007
U.S. locations: 22
States / cities: Beverly Hills, California • Burbank, California • Encino, California + 19 more

Conditions: Behavioral Symptoms, Autistic Disorder
Interventions: Aripiprazole, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 31
States / cities: Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 28 more

Conditions: Bipolar I Disorder, Depression, Anxiety, Stress
Interventions: Magnesium vitamin B6, Placebo; Drug
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years to 50 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Pain
Interventions: Acetaminophen, placebo; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 21 Years to 45 Years · Female only
Enrollment: 99 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Kidney Stone
Interventions: Flowmax, placebo; Drug
Lead sponsor: WellSpan Health; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: York, Pennsylvania

Conditions: Nonalcoholic Steatohepatitis
Interventions: SEL, FIR, CILO, Placebo to match FIR, Placebo to match CILO, Placebo to match SEL; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 395 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 81
States / cities: Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 62 more

Conditions: Healthy
Interventions: JTK-853, ketoconazole, JTK-853 or Placebo; Drug
Lead sponsor: Shionogi Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Arthritis, Rheumatoid
Interventions: CP-690,550, placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 509 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 33
States / cities: Gilbert, Arizona • Hot Springs, Arkansas • Upland, California + 26 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Ambrisentan, Placebo, Sildenafil, Tadalafil; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 16 Years to 75 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 30
States / cities: Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 25 more

Search by objective public record fields.

Safety And Efficacy Of 12 Weeks Of Varenicline For Smoking Cessation In Smokers With Depression

A Phase II, Double Blind Study of 2 Doses of ZACTIMA™(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in Patients

A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)

Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid Arthritis

A Phase 1, Study to Evaluate HTI-2088 Tablet

Dose Range Study of Anamorelin in Patients With Non-small Cell Lung Cancer

Effect of Eleclazine on Shortening of the QT Interval, Safety, and Tolerability in Adults With Long QT Syndrome Type 3

Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen®

Safety and Efficacy of Vilazodone in Adolescent Patients With Major Depressive Disorder

Double-blind Randomized Controlled Trial Comparing Suvorexant 20 mg to Placebo for Treatment of Insomnia in Cancer Survivors

Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)

Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) Taking Salmeterol Xinafoate/Fluticasone Propionate Combination

Safety and Efficacy Study of TNX-102 SL in Subjects With Military-Related PTSD and Related Conditions

A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)

Study Evaluating Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: The HEADWAY-DLB Study

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) In The Treatment Of Major Depressive Disorder

Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)

Efficacy and Safety of Magnesium Vitamin B6 in First Episode Bipolar Disorder

A Randomized Controlled Trial of Oral Acetaminophen for Analgesic Control After Transvaginal Oocyte Retrieval

Effect of Tamsulosin on Stone Expulsion and Pain Resolution in ED Patients With Ureterolithiasis

Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

Two Week Study Evaluating Safety, Tolerability and Pharmacokinetics of Multiple Doses of JTK-853 in Healthy Subjects

Comparison Of 6 CP-690,550 Doses Vs.Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid Arthritis

Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1)